Search results
Results from the WOW.Com Content Network
Coordinated Specialty Care (CSC) is a recovery-oriented treatment program designed for people with first episode psychosis (FEP). [1] CSC consists of collaborative treatment planning between the client and the client's care team, consisting of mental health clinicians, psychiatrists, and case managers.
More than 40 percent of all people with schizophrenia end up in supervised group housing, nursing homes or hospitals. Another 6 percent end up in jail, usually for misdemeanors or petty crimes, while an equal proportion end up on the streets. Among researchers, schizophrenia has long been known as the “graveyard of psychiatric research.”
A new first-in-class antipsychotic that targets multiple neurotransmitter systems called lumateperone (ITI-007), was trialed and approved by the FDA in December 2019 for the treatment of schizophrenia in adults. [24] [26] [27] Lumateperone is a small molecule agent that shows improved safety, and tolerance.
The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...
The Brief Negative Symptom Scale (BNSS) has been used to assess the effect of Ulotaront on the negative symptoms of schizophrenia. [18] In July 2023, the pharmaceutical company behind the drug announced that the drug had failed to outperform placebo in the treatment of acutely psychotic patients with schizophrenia, as measured by the PANSS. [19]
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb ...
(Reuters) -The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the first new type of antipsychotic medicine in decades. The ...
It is an official journal of the Schizophrenia International Research Society and was established in 1988. The editor-in-chief is Matcheri Keshavan and the former editors are Henry Nasrallah (University of Cincinnati) and Lynn DeLisi (Harvard Medical School). According to Schizophrenia Research 's original mission statement, the journal is aimed at